WG-103

人脐带间充质干细胞（茵冠生物）

Report date: 2026/01/13 13:43:41

Base Information

Drug NameWG-103
Drug Alias NameHuman umbilical cord-derived mesenchymal stem cell therapy (Yinguan Biological)WG103WG-103
ClassificationCell and gene therapy > Cell therapy > Source of cells > Umbilical cord-derivedCell and gene therapy > Cell therapy > Stem cell therapy > Mesenchymal stem cells therapy
Mechanisms of ActionStem cell replacements
TargetsNot applicable
Therapy Area/IndicationsIschemic StrokePrimary Ovarian InsufficiencyStroke +[6] 
Global Approved IndicationsN/A
Approved Indications in ChinaN/A
Original Approved Country/TerritoryN/A
Original Approved DateN/A
Country/TerritoryMainland China
CombinationsNo
Global Highest StatusPhase 2 Clinical
Highest Status in ChinaPhase 2 Clinical
Originator CompaniesShen Zhen Wingor Biotechnology Co Ltd
China Registration ClassClass 1 therapeutic biologic in China

Develop Information

Active CompaniesSoutheast UniversityShen Zhen Wingor Biotechnology Co Ltd
Inactive CompaniesN/A
Active IndicationsIschemic StrokePrimary Ovarian InsufficiencyStroke +[6] 
Inactive IndicationsN/A

Other Information

ATC CodeN/A
Related LinksN/A